Welcome, Guest. Please login or register.
June 15, 2024, 01:01:54 am

Login with username, password and session length

  • Total Members: 6309
  • Latest: Vicki
  • Total Posts: 55127
  • Total Topics: 4851
  • Online Today: 110
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 110
Total: 110


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Good Results for Real-World Treatment of Hep C in Those With Advanced Liver Dise  (Read 5514 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
In real-world practice, direct-acting antivirals (DAAs) work well in treating hepatitis C virus (HCV) among those with advanced liver disease. However, as seen in clinical trials, cure rates are not as high as for those with less damaged livers. Also, the treatment success rate is particularly low for people with genotype 3 of hep C and advanced liver disease.
Publishing their findings in Alimentary Pharmacology & Therapy, researchers in the HCV-TARGET consortium, which includes 39 academic and 13 community health centers in the United States, Germany, Israel and Canada, analyzed data on 240 people with advanced liver disease who started hep C treatment between December 2013 and October 2014.



© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.